10-Q: DURECT Corporation Reports Second Quarter 2024 Financial Results Amidst Going Concern Uncertainty

Sentiment:

Quarterly Report 14 August 2024 4:01 PM

DURECT Corporation's Q2 2024 results show a net loss of $3.7 million and highlight concerns about the company's ability to continue as a going concern due to insufficient cash resources.

Capital raiseThe company is seeking additional funding through collaborative agreements, public offerings, and private placements of its common stock, preferred stock offerings, issuances of debt and convertible debt instruments.The company has $222.7 million of securities available for sale under its 2021 shelf registration statement, but is limited to $18.1 million due to SEC rules.The company may decide to raise additional capital through a variety of sources in the short-term and in the long-term, including but not limited to the public equity markets, private equity financings, collaborative arrangements, asset sales, and/or public or private debt.

Worse than expectedThe company's net loss and decreased cash reserves are worse than expected.The company's going concern status is worse than expected.The discontinuation of PERSERIS sales by Indivior is worse than expected.

Summary

DURECT Corporation reported a net loss of $3.7 million for the three months ended June 30, 2024, and a net loss of $11.3 million for the six months ended June 30, 2024.
The company's cash, cash equivalents, and investments totaled $15.8 million as of June 30, 2024, down from $29.8 million at the end of 2023.
Collaborative research and development revenue was $606,000 for the quarter and $1.1 million for the six months ended June 30, 2024.
Product revenue was $1.6 million for the quarter and $2.9 million for the six months ended June 30, 2024.
Research and development expenses were $2.2 million for the quarter and $6.4 million for the six months ended June 30, 2024.
The company has an accumulated deficit of $600.3 million as of June 30, 2024.
DURECT's auditors have raised substantial doubt about the company's ability to continue as a going concern due to insufficient cash resources to meet its plans for the next twelve months.
The company is seeking additional funding through collaborative agreements, public offerings, and private placements.
The company's term loan is classified as a current liability due to repayment obligations, recurring losses, liquidity concerns and a subjective acceleration clause.

Sentiment

Score: 3

Explanation: The document presents a mixed picture. While there are positive clinical trial results for larsucosterol and a Breakthrough Therapy Designation, the company's financial situation and going concern status are major concerns. The discontinuation of PERSERIS sales further dampens the outlook. Overall, the negative aspects outweigh the positives, resulting in a low sentiment score.

Positives

Larsucosterol demonstrated a compelling efficacy signal in reducing mortality in the AHFIRM trial, particularly in the U.S. cohort.
The FDA granted Breakthrough Therapy Designation to larsucosterol, which could expedite its development and approval.
The company is planning to initiate a Phase 3 clinical trial for larsucosterol in 2024.
DURECT has a licensing agreement with Innocoll for POSIMIR, which provides a royalty stream.
The company has a royalty agreement with Orient Pharma for Methydur sales.

Negatives

DURECT reported a significant net loss of $3.7 million for the quarter and $11.3 million for the six months ended June 30, 2024.
The company's cash reserves have decreased significantly, raising concerns about its ability to continue as a going concern.
The company's term loan is classified as a current liability due to recurring losses and liquidity concerns.
Indivior has announced the discontinuation of sales and marketing for PERSERIS, which will negatively impact DURECT's earn-out revenue.
The company's ability to raise capital through its shelf registration statement is limited by SEC rules.

Risks

The company's ability to continue as a going concern is in doubt due to insufficient cash resources.
DURECT may not be able to secure additional funding on favorable terms, if at all.
The company's debt repayment obligations under the Loan Agreement may prove a burden.
The company's ability to raise capital in the public capital markets is limited by SEC rules.
The discontinuation of PERSERIS sales by Indivior will negatively impact DURECT's revenue.
The company's research and development programs are subject to numerous risks and uncertainties.
The company may have to relinquish rights to certain of its products, technologies or potential markets if it cannot raise sufficient capital.

Future Outlook

DURECT plans to initiate a Phase 3 clinical trial for larsucosterol in 2024, with topline results expected by the second half of 2026, subject to obtaining sufficient funding. The company expects to incur continuing losses and negative cash flows from operations for the foreseeable future and has substantial doubt about its ability to continue as a going concern.

Management Comments

Management is seeking additional funding through collaborative agreements, public offerings, and private placements.
Management expects research and development expenses in the near future to be comparable to the second quarter of 2024.
Management expects selling, general and administrative expenses in the near future to be comparable to the second quarter of 2024.

Industry Context

The announcement comes at a time when the biopharmaceutical industry is facing increased scrutiny on clinical trial results and financial sustainability. The discontinuation of PERSERIS by Indivior highlights the competitive nature of the pharmaceutical market and the challenges of commercializing new drugs. DURECT's focus on larsucosterol for alcohol-associated hepatitis addresses a significant unmet medical need, but the company's financial situation presents a major hurdle.

Comparison to Industry Standards

DURECT's financial performance is weaker than many of its peers in the biopharmaceutical industry, particularly those with commercialized products.
Companies like Gilead Sciences and Vertex Pharmaceuticals, which have established revenue streams from marketed drugs, have significantly stronger financial positions.
DURECT's reliance on external funding and collaborative agreements is common among early-stage biotechs, but the company's going concern status is a significant concern.
The clinical trial results for larsucosterol, particularly the mortality reduction in the U.S. cohort, are promising and could be competitive with other therapies in development for alcohol-associated hepatitis.
However, the lack of statistical significance in the primary endpoint of the AHFIRM trial is a setback compared to industry standards for successful Phase 2b trials.

Stakeholder Impact

Shareholders face significant risk due to the company's going concern status and potential dilution from future capital raises.
Employees may be concerned about job security due to the company's financial instability.
Customers of ALZET osmotic pumps may be impacted if the company's operations are curtailed.
Collaborators may be hesitant to enter into new agreements due to the company's financial situation.
Creditors face increased risk of non-payment due to the company's financial difficulties.

Next Steps

The company plans to initiate a Phase 3 clinical trial for larsucosterol in 2024, subject to obtaining sufficient funding.
The company will continue to seek additional funding through various sources.
The company will provide additional details of the Phase 3 trial design following receipt of the written minutes from the Type B meeting with the FDA.

Key Dates

Date	Description
February 6, 1998	DURECT Corporation was incorporated in the state of Delaware.
July 2016	DURECT entered into a $20.0 million secured term loan agreement with Oxford Finance LLC.
September 2017	DURECT entered into an agreement with Indivior for the assignment of certain patents related to PERSERIS.
February 2019	Indivior commercially launched PERSERIS in the U.S.
February 2021	POSIMIR received FDA approval for post-surgical pain reduction.
December 21, 2021	DURECT entered into a license agreement with Innocoll for POSIMIR.
August 2021	DURECT's shelf registration statement on Form S-3 was declared effective.
September 2022	Innocoll launched POSIMIR in the U.S.
February 3, 2023	DURECT entered into a securities purchase agreement for a registered direct offering.
February 8, 2023	Issuance date of common stock, pre-funded warrants and common warrants from the February 2023 offering.
June 1, 2023	Interest-only payments under the amended Loan Agreement ended, with consecutive monthly payments of principal and interest starting.
July 19, 2023	DURECT entered into a securities purchase agreement for a registered direct offering.
July 21, 2023	Issuance date of common stock and common warrants from the July 2023 offering.
November 2023	DURECT announced topline data from the AHFIRM trial and all 300,000 pre-funded warrants were exercised.
March 28, 2024	DURECT filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
May 2024	The FDA granted Breakthrough Therapy Designation to larsucosterol.
June 30, 2024	End of the reporting period for the second quarter of 2024.
July 2024	DURECT held a Type B meeting with the FDA to discuss the design of the Phase 3 clinical trial for larsucosterol and Indivior announced discontinuation of sales and marketing for PERSERIS.
August 9, 2024	Date of outstanding shares of common stock and employee count.
August 14, 2024	Date of the filing of the Quarterly Report on Form 10-Q.
August 16, 2024	The 2021 Registration Statement expires.
September 1, 2025	Final maturity date of the term loan.
Second half of 2026	Expected topline results from the Phase 3 clinical trial for larsucosterol.

Keywords

Larsucosterol, Alcohol-associated hepatitis, AH, Clinical trial, Breakthrough Therapy Designation, POSIMIR, Financial results, Going concern, Net loss, Cash resources, Term loan, PERSERIS, Methydur, FDA

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.